Session 4: Immunology of HIV Persistence

08h00-10h00

moderator

Chairs: Katharine BAR, Philadelphia - Bradley JONES, New York

Viral persistence and NK cells

Michaela MULLER-TRUTWIN, Badalona

Cytolytic CD8+ T cells infiltrate germinal centers and limit HIV replication in spontaneous controllers

Julia HITSCHFEL, Albany

LEAKY RESERVOIRS ARE ASSOCIATED WITH HIV-SPECIFIC CD4 AND CD8 T CELL RESPONSES

Mathieu DUBÉ, Frederick

HIV reservoir burden associates with numbers of HIV-specific CD8+ T cells under long-term antiretroviral therapy and prevents them from differentiating into functional memory cells

Hiroshi TAKATA, Beaverton

Comparative single-cell transcriptome and TCR profiling of HIV infected cells in the blood and cerebrospinal fluid of PLWH before and after ART

Meng WANG, New Haven

NO ASSOCIATIONS BETWEEN MAGNITUDES OF HIV-SPECIFIC CTL RESPONSES ON STABLE ART AND SUBSEQUENT DECAY OF INTACT PROVIRUSES OR CELL-ASSOCIATED HIV Mrna

Adam WARD, New York

CIRCULATING IMMUNE PREDICTORS OF INTACT HIV RESERVOIR DECAY DURING LONG-TERM ART

Michael PELUSO, Philadelphia

CD8+ T CELLS PROMOTE HIV LATENCY IN CD4+ T CELLS THROUGH THE DOWNMODULATION OF NF-Kb

Simona MUTASCIO, Paris

Session 5: Drug Discovery Development & Pharmacology

10h30-12h30

moderator

Chairs: Jan VAN LUNZEN, London - Romas GELEZIUNAS, Foster City

IAP inhibitors to induce HIV expression

Richard DUNHAM, Burnaby

Characterization of a dual PTPN1/PTPN2 inhibitor to target latent HIV reservoirs

Alberto BOSQUE, Washington

1-year treatment with ponatinib provides protection of CD4+ T cells against HIV that is maintained at least 1 year more after treatment interruption

Mario MANZANARES, Brookline

Identification and characterization of novel inhibitors of HIV Tat protein

Sonia MEDIOUNI JABLONSKI, Orlando

Impairment of HIV proviral reactivation by interfering with essential metabolic pathways in effector memory CD4+ T cells

Guiomar CASADO FERNÁNDEZ, Frederick

Enhancing PKC Modulator HIV Latency Reversing Agents

Matthew MARSDEN, Chapel Hill

Romidepsin in combination with the BCL-2 antagonist venetoclax synergistically reduce the size of the HIV reservoir

Youry KIM, Philadelphia

Session 6: Cell & gene therapies

14h00-16h00

moderator

Chairs: Tricia BURDO, Philadelphia - Javier MARTINEZ-PICADO, Badalona

It’s a mountain not a hill: Progress made in realizing AAV-delivered inhibitors for an HIV cure

Mathew GARDNER, New York

TARGETED GENOME ENGINEERING OF HUMAN T CELLS IN VIVO FOR HIV CURE

Priti KUMAR, Baltimore

Delivery and long-term expression of CCR5-blocking monoclonal antibody Leronlimab with AAV for ART-free remission from SHIV viremia

Gabriela WEBB, Beaverton

High-efficiency CRISPR/Cas9-mediated disruption of ccr5 in human hematopoietic stem progenitor cells generates HIV-refractory immune systems

Daniel CLAIBORNE, Los Angeles

Viral Suppression in SHIV-infected Rhesus Macaques following AAV-mediated Delivery of Closer-to-germline Monoclonal Antibodies

Jose MARTINEZ-NAVIO, Miami

Long-term ART-free SIV Remission Following Allogeneic Hematopoietic Cell Transplantation in Mauritian Cynomolgus Macaques

Helen WU, Beaverton

Young investigators session 2

16h00-17h00

moderator

Chairs: Afam OKOYE, Beavertown - Katharine BAR, Philadelphia

Bispecific antibodies promote natural killer cell-mediated elimination of the HIV reservoir

Nathan BOARD, Baltimore

Investigating the Role of Naïve CD4+ T-cells as a CTL Resistant Sanctuary for Intact HIV Proviruses

Jared WEILER, New York

Impact of early antiretroviral therapy on tissue resident myeloid cells in the liver and lung of SIV-infected rhesus macaques

Julien CLAIN, Worcester

HIV persistence and latency in microglia: Single-cell transcriptome analysis of three humanized mice models of HAND shows viral responses to inflammatory signaling

Konstantin LESKOV, New York

DISTINCT HIV-1 RESISTANCE PROFILES AGAINST BNAB IN INTACT VS DEFECTIVE VIRAL GENOMES

Guinevere LEE, Hamburg

Investigating Short-Term Effects of COVID-19 mRNA Vaccination on Plasma Viremia and Intact HIV Reservoir Size in Individuals Receiving Antiretroviral Therapy (ART)

Maggie DUNCAN, Montreal

The level of cell activation is associated with the pre-integrative latency of HIV linear DNA

Jacques DUTRIEUX, Philadelphia

BMG Curated Session

10h00-12h00

Welcome & Introduction to the HIV Reservoirs Consortium

Heather Ann BRAUER, Seattle

High-Dimensional Spatial Characterization of Viral Reservoirs inTissues [20 min] and Q&A [5 min]

Jacob ESTES, Cary

Current Broadly Neutralizing Antibody Clinical Trials [15 Mins]The Rio Trial: Design, Implementation and Post Treatment Viral Control [15 MINS]Q&A [5 MINS]

Sarah FIDLER, Beaverton

Current Broadly Neutralizing Antibody Clinical Trials [15 Mins]The Rio Trial: Design, Implementation and Post Treatment Viral Control [15 MINS]Q&A [5 MINS]

Christian GAEBLER, Cleveland

Spatial Resolution of Virologic and Immunologic Characteristics of HIVReservoirs in Human Lymph Node Tissues Following Early ArtInitiation [20 MINS] Q&A [5 MINS]

Zaza NDHLOVU, Kampala

Analytical Treatment Interruption to Identify Host Biomarkers Predictiveof Viral Rebound [20 MINS] Q&A [5 MINS]

Lillian COHN, Worcester

NIH SATELLITE SYMPOSIUM 7 - PAVE

12h00-13h00

moderator

Chair: Deborah Persaud, Johns Hopkins University and Ann Chahroudi, Emory University

RF1: ITACO cohort

Mathias LICHTERFELD, San Francisco

RF2: AAV vector delivery

Mauricio MARTINS, Miami

RF3: IL-15

Ann CHAHROUDI, New York

RF4: IPDA Development

Deborah PERSAUD, Bethesda

Tissues: Macrophage, CNS reservoir and viremia

Katherine RUIZ DE LUZURIAGA, Baltimore

NIH SATELLITE SYMPOSIUM 1 - Beat-HIV

13h35-13h55

moderator

Chair: Luis Montaner, Wistar Institute

RF1: BEAT2 primary trial outcomes: PEG-IFN-A2B + 3BNC117 & 10-1074 in chronic HIV infection

Luis MONTANER, Pittsburgh

RF2: High-efficiency ablation of CCR5 in hematopoietic stem cells generates HIV-refractory immune systems

Daniel CLAIBORNE, Worcester

RF3: Targeted LNP-mRNA therapeutics for HIV cure

Hamideh PARHIZ, Gent

Tissues: A NHP model of CNS persistence

Katharine BAR, Philadelphia

NIH SATELLITE SYMPOSIUM 2 - Reach

14h00-14h20

moderator

Chair: Brad Jones, Weill Cornell Medicine

RF1: Interpreting on-ART proviral diversity in context of HIV’s within-host evolutionary history enriches our understanding of reservoir dynamic

Zabrina BRUMME, Burnaby

RF2: Updates on bNAb Cure Studies and Implications for Future Studies

Marina CASKEY, New York

RF3: Resistance to Cytotoxicity in HIV-infected CD4 Cells

Brad JONES, Chapel Hill

Tissues: A story of survival: characterizing HIV-infected macrophages that resist NK cell-mediated killing

Kiera CLAYTON, Québec

NIH SATELLITE SYMPOSIUM 3 - Care

14h25-14h45

moderator

Chair: David Margolis, University of North Carolina Chapel Hill

RF1: New approaches to HIV Latency Biology and Therapeutics

Anne-Marie TURNER, Chapel Hill

RF2: HLA-E-mediated targeting for control of viral rebound

David MARGOLIS, Chapel Hill

RF3: Microglia: potential barrier to SIV eradication

Yuyang TANG, Chapel Hill

Tissues: Persistent HIV infection in the CNS

Guochun JIANG, Dresden

NIH SATELLITE SYMPOSIUM 4 - Erase-HIV

14h50-15h10

moderator

Chair: Mirko Paiardini, Emory University

RF1: CD8+ T cells promote HIV latency in CD4+ T cells through the downmodulation of NF-KB

Simona MUTASCIO, Atlanta

RF2: Reprograming CD8+ T cells to enhance their anti-HIV potential

Asier SAEZ-CIRION, Portland

RF3: Dynamics and antiviral role of TOX+ TCF1+ CD39+ CD8 T cells in lymphoid tissue of SIV-infected rhesus macaques

Mirko PAIARDINI, Beaverton

Tissues: Macrophages are the primary source of virus in semen in SIV-infected rhesus macaques

Claire DELEAGE, Frederick

NIH SATELLITE SYMPOSIUM 5 - I4C

15h40-16h00

moderator

Chair: Dan Barouch, Beth Israel Deaconess Medical Center, Harvard Medical School

RF1: HLA association with HIV disease outcomes implicates novel effect of NK cells

Rasmi THOMAS, Silver Spring

RF2: Progress in Engineering B-cells to Produce bNAbs

John MELLORS, Jupiter

RF3: Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques

Victoria WALKER-SPERLING, Boston

Tissues: CNS Investigations in I4C

Sandhya VASAN, Bethesda

NIH SATELLITE SYMPOSIUM 6 - CRISPR for Cure

16h05-16h25

moderator

Chair: Tricia H. Burdo, Temple University

RF1: Dynamics of NK Cell Responses to HIV-1 Infection in humanized mice

Liang SHAN, St. Louis

RF2: Use of barcoded SIV and full-length sequencing for detecting viral reservoirs after CRISPR

Tricia BURDO, Philadelphia

RF3: Developing library of safe and universal multiplex gRNAs for efficient editing of HIV & SIV pro viral DNA by CRISPR

Kamel KHALILI, Frederick

Tissues: HIV persistence and latency in microglia: Single-cell transcriptome analysis of three humanized mice models of HAND shows viral responses to inflammatory signaling

Konstantin LESKOV, Cleveland

NIH SATELLITE SYMPOSIUM 8 - HOPE

16h30-16h55

moderator

Chair: Melanie Ott, Gladstone Institute of Virology and Immunology

RF1: A new supercomplex transcriptionally silencing HIV-1

Zichong LI, Cleveland

RF2: Targeting HIV-1 Tat via protein degradation

Susana VALENTE, Jupiter

RF3: Targeted genome engineering of human T cells in vivo for HIV cure

Priti KUMAR, New Haven

Tissues: Spironolactone represses HIV-1 driven transcription in human microglia and T cell models of latency and alters DNA methylation of metabolic genes

Alina PANG, Westmead

NIH SATELLITE SYMPOSIUM 9 - DARE

17h15-15h35

moderator

Chair: Sharon Lewin, University of Melbourne

RF1: Impact of therapeutic vaccination on measures of HIV persistence

Kara CHEW, Paris

RF2: Targeting post-ART viral rebound with SIV neutralizing antibodies

Afam OKOYE, Lake Worth

RF3: Romidepsin synergistically reduces the levels of HIV DNA when combined with pro-apoptotic drugs

Youry KIM, Melbourne

Tissues: Chronic immune activation and gut barrier dysfunction is associated with neuroinflammation in ART- suppressed SIV+ rhesus macaques

Jacob ESTES, Beaverton

NIH SATELLITE SYMPOSIUM 10 - RID-HIV

17h40-18h00

moderator

Chair: Sumit Chanda, Scripps Research

RF1: Microbiome/metabolome associated mechanisms modulate Immune dysfunction and HIV Persistence

Ashish SHARMA, Atlanta

RF2: Immuno-virological determinants of extremely low viral reservoirs in PWH on cARTvirological determinants of extremely low viral reservoirs in PWH on cAR

Maria SALGADO, Badalona

RF3: Killing reactivated cells by recruitment of NK cells

Sumit CHANDA, Decatur

Tissues: Lessons learned from HIV-1 STAR to be implemented in RID HIV

Laurens LAMBRECHTS, New Haven

NIH SATELLITE SYMPOSIUM 11 - Closing remarks

18h05-18h25

Closing remarks

Karl SALZWEDEL, Rockville

Welcoming Message and Opening Lecture

18h30-19h00

Welcoming Message

David MARGOLIS, Chapel Hill

Welcoming Message

Karl SALZWEDEL, Rockville

Welcoming Message

Mario STEVENSON, Miami

Lessons learned from allogeneic stem cell transplantation in HIV + Patients

Gero HÜTTER, Somerville

Session 1: Basic science of HIV persistence

08h00-10h00

moderator

Chairs: Maria SALGADO, Badalona - Nancy ARCHIN, Chapel Hill

Sequencing HIV: Significance and Impact

Sarah PALMER, Atlanta

HIV Silencing and Cell Survival Signatures of HIV-Infected CD4 T Cell Transcriptomes under Antiretroviral Therapy (ART)

Eli BORITZ, Bethesda

THE FRACTION OF CELLS WITH UNSPLICED HIV RNA IS NOT ASSOCIATED WITH PLASMA VIREMIA

Adam CAPOFERRI, Paris

Definitive evidence of a persistent HIV reservoir in human brain myeloid cells despite ART

Yuyang TANG, Chapel Hill

P400/Tip60 chromatin remodeling complex in HIV transcription and latency establishment

Luisa MORI, Philadelphia

Role of UHRF1 in HIV-1 transcriptional repression through epigenetic and non-epigenetic mechanisms

Carine VAN LINT, Brussels

Potent latency reversal enables in-depth transcriptomic analysis of the translation-competent HIV-1 reservoir

Marion PARDONS, New York

Session 2: In Vitro and Animal Model Studies of HIV Persistence

10h30-12h30

moderator

Chairs: Afam OKOYE, Beavertown - Ann CHAHROUDI, Yerkes

CCR5 blockade in HIV cure

Jonah SACHA, Worcester

Characterization of the SIV tissue reservoir transcriptional environment at the single focus level during ART and post ATI

Ramon LORENZO-REDONDO, Lafayette

The EZH2 inhibitor Tazemetostat increases MHC I antigen presentation in vitro and in vivo, enhancing antiviral activities of HIV-specific CTLs

Andrea GRAMATICA, London

No Evidence of Ongoing Viral Replication in SIV-Infected Macaques on Combination Antiretroviral Therapy Initiated in the Chronic Phase of Infection Despite Elevated Residual Plasma Viral Loads

Gregory DEL PRETE, Brooklyn

Targeting the SIV reservoir with Alemtuzumab

Benjamin VARCO-MERTH, Beaverton

Constitutive NKG2A levels and timing of antiretroviral therapy initiation impact the potential role of NK cells after treatment interruption -the pVISCONTI study

Anaïs CHAPEL, La Jolla

The latency reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific CD8+ T-cells

Dennis COPERTINO, Seattle

Session 3: Virology of HIV Persistence

14h00-16h00

moderator

Chairs: Ya-Chi HO, Yale - Mary KEARNEY, Frederick

HIV Persistence in women, an update

Nancie ARCHIN, Chapel Hill

Clonally expanded HIV-1 proviruses with 5’-Leader defects can give rise to nonsuppressible residual viremia and complicate ART management

Francesco SIMONETTI, Baltimore

Inducible replication-competent HIV proviruses persist in memory CD4+ T cells expressing high levels of the integrin VLA-4 (?4?1)

Caroline DUFOUR, Montréal

INFECTED NAÏVE CD4+ T CELLS IN CHILDREN WITH HIV CAN PROLIFERATE AND PERSIST ON ART

Mary Grace KATUSIIME, New York

HIV-1 RNA+ infected CD4 T cell burden in acute HIV-1 infection and association with inflammatory markers

Diane BOLTON, Silver Spring

Effect of HIV-1 infection, viral particle production, and proviral integration site on CD4+ T cell proliferation

Joshua KUFERA, Bethesda

Cohort-specific Adaptation of the Intact Proviral DNA Assay (IPDA) to HIV-1 subtypes A1, D, and recombinants

Sarah GOWANLOCK, Philadelphia

Young investigators session 1

16h00-17h00

moderator

Chairs: Nancy ARCHIN, Chapel Hill - Susana VALENTE, Jupiter

Histone decrotonylation uniquely regulates HIV-1 transcription and can be modulated to control HIV-1 latency

Theresa SIMERMEYER, Durham

LAIR-1 is a negative regulator of SIV-specific CD8 T cells during chronic SIV infection

Vijayakumar VELU, Atlanta

Continuous decline of intact proviral DNA after two decades of antiretroviral therapy

Marieke NÜHN, Durban

The HIV-1 antisense RNA Ast promotes viral latency via epigenetic silencing of the proviral 5’LTR and is expressed in latently infected cells from ART-suppressed donors

Riui LI, Minneapolis

CAR/CXCR5 T cells contact HIV vRNA+ cells in HIV-infected humanized DRAGA mice

Pongthorn PUMTANG-ON, Badalona

Multiomic dynamics of the cellular HIV reservoir after rebound during ATI

Vincent WU, Philadelphia

Session 7: Human studies

08h00-10h00

moderator

Chairs: Lydie TRAUTMANN, Beavertown - David MARGOLIS, Chapel Hill

Challenges and Advances in Identification and Immune Targeting of HIV-Infected Cells: Implications for HIV Cure Therapies

Timothy HENRICH, New York

Impact of 10-1074LS and 3BNC117-LS on viral rebound dynamics following treatment interruption six months after dosing: four cases from the open label arm of the RIO trial

Ming LEE, London

Pre-treatment Interruption Plasma Metabolites and Glycans Correlate with Time to HIV Rebound and Reservoir Size in ACTG A5345

Leila GIRON, Atlanta

Series of Jojo. A way to disseminate HIV Cure information in a community language.

Josephine NABUKENYA, Atlanta

Measuring the impact of early 3BNC117 intervention at ART initiation on the productive reservoir in a cohort of diverse viral subtypes: results from the VIP-SPOT assay in the eCLEAR trial

Maria C. PUERTAS, Baltimore

Clonal Dynamics within HIV-Infected CD4 T Cell Reservoirs after PD-1 Blockade under ART

Liliana PÉREZ, San Francisco

CHARACTERIZATION OF THE HIV-1 VIRAL RESERVOIR IN SUBTYPE B EARLY TREATED INDIVIDUALS

Tine STRUYVE, Ghent

Session 8: Antibodyes & immune based therapies

10h30-12h30

moderator

Chairs: Michael FARZAN, San Diego - Marina CASKEY, Rockefeller

Broadly Neutralizing Antibodies for HIV Prevention, Therapy and Cure: 3BNC117 & 10-1074 Studies

Marina CASKEY, Madrid

Interleukin-2 administration is a potent latency reversal agent in people with treated HIV infection

Michael FREEMAN, London

HIV-vaccine induced, broad and polyfunctional CD4 and CD8 T cell responses are associated with prolonged time off ART and lower pVL at the end of ATI in the AELIX-002 therapeutic vaccine trial

Beatriz MOTHE, Jupiter

TLR agonist and SIV mAbs administered to SIV-infected ART-suppressed macaques did not delay rebound after treatment interruption

Hannah KING, Melbourne

TGF-beta Blockade to Stop HIV White Noise: a New “Release and Kill” HIV Strategy

Elena MARTINELLI, Irvine

Autologous neutralizing antibody responses in bnAb-treated rhesus macaques

Katherine BAR, Atlanta

In vivo evolution of env in SHIV-AD8-infected rhesus macaques after AAV-eCD4-Ig therapy

Daniel O'HAGAN, Utrecht

Closing ceremony

12h30-13h00